Skip to main content

Table 2 Univariate analysis of clinical outcomes

From: BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma

Variable Local–Regional (LN) Control P DMFS P RFS P OS P
BRAF status
 Negative 0.03 0.89 0.45 0.72
 Positive 2.7 (1.1–6.5)   0.96 (0.58–1.6)   1.20 (0.75–1.9)   1.11 (0.63–2.0)  
Gender
 Male 0.12 0.89 0.87 0.87
 Female 0.46 (0.17–1.2)   0.93 (0.55–1.6)   1.04 (0.63–1.7)   0.95 (0.52–1.7)  
Age
 ≤ 50 yrs 0.54 0.55 0.60 0.22
 < 50 yrs 0.77 (0.33–1.8)   1.12 (0.69–2.0)   1.14 (0.69–1.9)   1.46 (0.79–2.7)  
Location of primary
 Other 0.99 0.57 0.71 0.23
 Trunk 1.01 (0.35–2.9)   0.80 (0.38–1.7)   0.86 (0.43–1.8)   0.57 (0.23–1.4)  
Depth of invasion
 ≤ 2 mm 0.94 0.70 0.91 0.51
 < 2 mm 1.04 (0.43–2.5)   1.11 (0.64–1.9)   0.97 (0.58–1.6)   0.82 (0.45–1.5)  
Ulceration of primary
 No 0.95 0.67 0.89 0.61
 Yes 1.04 (0.36–2.9)   1.15 (0.61–2.1)   0.96 (0.53–1.7)   1.20 (0.60–2.4)  
# of Mitosis in primary
 ≤ 5 0.74 0.83 0.86 0.72
 > 5 1.20 (0.41–3.4)   1.1 (0.56–2.0)   1.01 (0.58–1.9)   1.13 (0.57–2.3)  
# of LNs positive
 < 4 0.01 0.09 0.03 0.02
 ≥ 4 3.34 (1.4–8.2)   1.72 (0.92–3.2)   1.88 (1.1–3.4)   2.26 (1.19–4.3)  
ECE
 No 0.85 0.60 0.87 0.79
 Yes 0.91 (0.35–2.4)   1.18 (0.62–2.2)   0.95 (0.52–1.7)   1.09 (0.56–2.1)  
Size of LN deposit
 ≤ 30 mm 0.11 0.32 0.47 0.93
 > 30 mm 0.41 (0.14–1.2)   1.35 (0.75–2.4)   1.23 (0.70–2.1)   0.97 (0.51–1.9)  
RT dose
 ≤ 30 Gy 0.99 0.98 0.72 0.57
 > 30 Gy 0.99 (0.46–2.2)   0.99 (0.60–1.6)   1.1 (0.68–1.8)   0.85 (0.48–1.5)  
Time from LND to RT
 ≤ 3 mos 0.55 0.88 0.76 0.81
 > 3 mos 0.54 (0.7–4.0)   1.08 (0.39–3.0)   0.85 (0.30–2.4)   1.14 (0.41–3.2)  
Adjuvant systemic Tx
 No 0.46 0.07 0.04 0.25
 Yes 0.74 (0.34–1.6)   0.63 (0.38–1.0)   0.61 (0.4–0.99)   0.72 (0.41–1.3)